Tsg101 Is Essential for Cell Growth, Proliferation, and Cell Survival of Embryonic and Adult Tissues

REFERENCES

• Babst, M., G. Odorizzi, E. J. Estepa, and S. D. Emr. 2000. Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking. Traffic 1: 248–258.
   PubMed Web of Science ®Google Scholar
• Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552–557.
   PubMed Web of Science ®Google Scholar
• Carney, M. E., G. L. Maxwell, J. M. Lancaster, C. Gumbs, J. Marks, A. Berchuck, and P. A. Futreal. 1998. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. J. Soc. Gynecol. Investig. 5: 281–285.
   PubMedGoogle Scholar
• Caulin, C., G. S. Salvesen, and R. G. Oshima. 1997. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell Biol. 138: 1379–1394.
   PubMed Web of Science ®Google Scholar
• Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675–684.
   PubMed Web of Science ®Google Scholar
• Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Cote, R. L. Rich, D. G. Myszka, and W. I. Sundquist. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107: 55–65.
   PubMed Web of Science ®Google Scholar
• Gayther, S. A., P. Barski, S. J. Batley, L. Li, K. A. de Foy, S. N. Cohen, B. A. Ponder, and C. Caldas. 1997. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 15: 2119–2126.
   PubMed Web of Science ®Google Scholar
• Hittelman, A. B., D. Burakov, J. A. Iniguez-Lluhi, L. P. Freedman, and M. J. Garabedian. 1999. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J. 18: 5380–5388.
   PubMed Web of Science ®Google Scholar
• Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206–208.
   PubMed Web of Science ®Google Scholar
• Koonin, E. V., and R. A. Abagyan. 1997. TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat. Genet. 16: 330–331.
   PubMed Web of Science ®Google Scholar
• Krempler, A., M. D. Henry, A. A. Triplett, and K. U. Wagner. 2002. Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53 independent cell death. J. Biol. Chem. 277: 43216–43223.
   PubMed Web of Science ®Google Scholar
• Lee, M. P., and A. P. Feinberg. 1997. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res. 57: 3131–3134.
   PubMed Web of Science ®Google Scholar
• Li, L., and S. N. Cohen. 1996. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85: 319–329.
   PubMed Web of Science ®Google Scholar
• Li, L., X. Li, U. Francke, and S. N. Cohen. 1997. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 88: 143–154.
   PubMed Web of Science ®Google Scholar
• Li, L., J. Liao, J. Ruland, T. W. Mak, and S. N. Cohen. 2001. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. USA 98: 1619–1624.
   PubMedGoogle Scholar
• Li, M., K. U. Wagner, and P. A. Furth. 2000. Transfection of primary mammary epithelial cells by viral and nonviral methods, p. 233–244. In M. M. Ip and B. B. Ash, (ed.), Methods in mammary gland biology and breast cancer. Kluwer Academic/Plenum Publishers, New York, N.Y.
   Google Scholar
• Lin, S. F., P. M. Lin, T. C. Liu, J. G. Chang, Y. C. Sue, and T. P. Chen. 2000. Clinical implications of aberrant TSG101 transcripts in acute myeloblastic leukemia. Leuk. Lymphoma 36: 463–466.
   PubMed Web of Science ®Google Scholar
• Loonstra, A., M. Vooijs, H. B. Beverloo, B. A. Allak, E. van Drunen, R. Kanaar, A. Berns, and J. Jonkers. 2001. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc. Natl. Acad. Sci. USA 98: 9209–9214.
   PubMed Web of Science ®Google Scholar
• Martin-Caballero, J., J. M. Flores, P. Garcia-Palencia, and M. Serrano. 2001. Tumor susceptibility of p21 (Waf1/Cip1)-deficient mice. Cancer Res. 61: 6234–6238.
   PubMed Web of Science ®Google Scholar
• Medina, D. and F. S. Kittrell. 2000. Establishment of mouse mammary cell lines, p. 137–145. In M. M. Ip and B. B. Ash (ed.), Methods in mammary gland biology and breast cancer. Kluwer Academic/Plenum Publishers, New York, N.Y.
   Google Scholar
• Montes de Oca, L. R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206.
   PubMed Web of Science ®Google Scholar
• Oh, H., C. Mammucari, A. Nenci, S. Cabodi, S. N. Cohen, and G. P. Dotto. 2002. Negative regulation of cell growth and differentiation by TSG101 through association with p21Cip1/WAF1. Proc. Natl. Acad. Sci. USA 99: 5430–5435.
   PubMedGoogle Scholar
• Ponting, C. P., Y. D. Cai, and P. Bork. 1997. The breast cancer gene product TSG101: a regulator of ubiquitination? J. Mol. Med. 75: 467–469.
   PubMedGoogle Scholar
• Ruland, J., C. Sirard, A. Elia, D. MacPherson, A. Wakeham, L. Li, D. L. P. Luis, S. N. Cohen, and T. W. Mak. 2001. p53 Accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc. Natl. Acad. Sci. USA 98: 1859–1864.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12: 2984–2991.
   PubMed Web of Science ®Google Scholar
• Silver, D. P., and D. M. Livingston. 2001. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol. Cell 8: 233–243.
   PubMed Web of Science ®Google Scholar
• Steiner, P., D. M. Barnes, W. H. Harris, and R. A. Weinberg. 1997. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nat. Genet. 16: 332–333.
   PubMed Web of Science ®Google Scholar
• Sun, Z., J. Pan, G. Bubley, and S. P. Balk. 1997. Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene 15: 3121–3125.
   PubMed Web of Science ®Google Scholar
• Turpin, E., B. Dalle, A. de Roquancourt, L. F. Plassa, M. Marty, A. Janin, Y. Beuzard, and H. de The. 1999. Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers. Oncogene 18: 7834–7837.
   PubMedGoogle Scholar
• Wagner, K. U., C. A. Boulanger, M. D. Henry, M. Sgagias, L. Hennighausen, and G. H. Smith. 2002. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 129: 1377–1386.
   PubMedGoogle Scholar
• Wagner, K. U., P. Dierisseau, and L. Hennighausen. 1999. Assignment of the murine tumor susceptibility gene 101 (tsg101) and a processed tsg101 pseudogene (tsg101-ps1) to mouse chromosome 7 band B5 and chromosome 15 band D1 by in situ hybridization. Cytogenet. Cell Genet. 84: 87–88.
   PubMedGoogle Scholar
• Wagner, K. U., P. Dierisseau, E. B. Rucker, G. W. Robinson, and L. Hennighausen. 1998. Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene 17: 2761–2770.
   PubMed Web of Science ®Google Scholar
• Wagner, K. U., K. McAllister, T. Ward, B. Davis, R. Wiseman, and L. Hennighausen. 2001. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res. 10: 545–553.
   PubMedGoogle Scholar
• Wagner, K. U., R. J. Wall, L. St-Onge, P. Gruss, A. Wynshaw-Boris, L. Garrett, M. Li, P. A. Furth, and L. Hennighausen. 1997. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 25: 4323–4330.
   PubMed Web of Science ®Google Scholar
• Wagner, K. U., W. S. Young, X. Liu, E. I. Ginns, M. Li, P. A. Furth, and L. Hennighausen. 1997. Oxytocin and milk removal are required for post-partum mammary-gland development. Genes Funct. 1: 233–244.
   PubMedGoogle Scholar
• Watanabe, M., Y. Yanagi, Y. Masuhiro, T. Yano, H. Yoshikawa, J. Yanagisawa, and S. Kato. 1998. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem. Biophys. Res. Commun. 245: 900–905.
   PubMedGoogle Scholar
• Xie, W., L. Li, and S. N. Cohen. 1998. Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc. Natl. Acad. Sci. USA 95: 1595–1600.
   PubMed Web of Science ®Google Scholar
• Xu, C. F., J. Greenman, and E. Solomon. 1998. Truncated TSG101 transcripts are present in peripheral blood from both familial breast cancer patients and controls. Eur. J. Cancer 34: 1077–1080.
   PubMedGoogle Scholar
• Xu, X., K. U. Wagner, D. Larson, Z. Weaver, C. Li, T. Ried, L. Hennighausen, A. Wynshaw-Boris, and C. X. Deng. 1999. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22: 37–43.
   PubMed Web of Science ®Google Scholar
• Zhong, Q., Y. Chen, D. Jones, and W. H. Lee. 1998. Perturbation of TSG101 protein affects cell cycle progression. Cancer Res. 58: 2699–2702.
   PubMedGoogle Scholar